Squarex Pharmaceutical Corpの株価・株式情報

Squarex Pharmaceutical Corporation is a pharmaceutical company. The Company is engaged in developing a late-clinical-stage drug to improve immune function to reduce severity and incidence of infectious disease with an initial focus on oral herpes. The Company's drug SQX770 has completed a Phase I and a Phase II placebo-controlled clinical trial. SQX770 contains the active ingredient squaric acid dibutyl ester (SADBE). The SQX770 drug is topically applied on a patient's arm, not the face or lip or a lesion.